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Design
• Quasi-experimental design in Oddar Meanchay 
province, Cambodia.
• Post-training, each of the 94 HCW/VMWs (age 18-
69yrs) performed on average 10 G6PD RDT tests on 
960 adult males. 
• Performance of CareStart™ RDT for G6PDd screening 
was assessed against quantitative G6PD test (Pointe 
Scientific, Inc. Canton MI). 
• Pre/post-training questionnaires completed by 
HCW/VMWs and G6PD volunteers. 
Blood sample collection
• Study was conducted from Dec, 2017 to Feb, 2018.
• Finger prick blood sample was obtained  for 
CareStart™ RDT testing in the field.
Knowledge about PQ and G6PD screening
Primaquine (PQ) is the only FDA-approved drug for 
radical cure of Plasmodium vivax (P.v) malaria but 
treatment can result in life-threatening hemolysis if given 
to a glucose-6-phosphate dehydrogenase deficient 
(G6PDd) patient. Therefore, the G6PD status of the 
patient with P.v must be known prior to prescribing PQ. To 
increase PQ access in Cambodia, performance of G6PD 
rapid diagnostic tests (RDTs) needs to be evaluated in 
healthcare workers (HCWs) and village malaria workers 
(VMWs). 
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The G6PD RDT may enable 
safer application of PQ and 
reduce the burden of vivax 
malaria. Malaria workers 
need training on risks and 
benefits of PQ, G6PD 
testing and correct 
interpretation of G6PD RDT 
results in the field.
There is insufficient data on 
performance of G6PD RDT in 
field setting, and whether it 
matches the performance 
demonstrated in controlled lab 
settings by researchers.
• Assess the 
HCW/VMWs’ 
knowledge of PQ, their 
acceptability to test for 
G6PD using 
CareStart™, and 
willingness to give PQ 
when the G6PD status 
of the patient is known 
by RDT. 
• 2ml venous blood was collected in Vacutainer tubes (BD 
Vacutainer, Franklin Lakes, NJ) for CBC and quantitative 
G6PD testing in lab. 
Data Collection
 Demographics data was collected with questionnaires
 Perceptions on PQ risk and benefits and willingness to use 
G6PD RDTs for screening was evaluated
The RDT test results obtained by trainees in the field were 
compared against the performance of the RDT test by expert 
readers both in field and laboratory settings 
Primary Endpoint 
Assess the sensitivity, specificity, PPV and NPV of 
CareStart™ RDT in the field setting vs. the quantitative G6PD 
activity thresholds (“gold standard” for G6PDd diagnosis). 
Analysis:
• Descriptive and inferential statistics 
to evaluate the acceptability and 
effectiveness of training.
• Stata 15, SPSS, and Graphprism 7. 
Standard methods for calculating 
sensitivity, specificity, PPV & NPV 
were applied to the G6PD RDT (95% 
CI)..
Reference standard
• The G6PD spectrophotometric quantitative analysis was 
performed using a Pointe G6PD reagent kit (Pointe 
Scientific, Inc. MI, USA). 
The pre/post training questionnaires assessed trainee 
knowledge, and perception of PQ risk and  willingness 
to give PQ based on G6PD status by RDT.
All scores improved post training








Willingness to test for G6PD 






Level of comfort in giving PQ 





Level of comfort in giving PQ to 






Willingness to give a patient  PQ 






156/960 (16%) diagnosed as G6PDd (< 2.505) 
The distribution of G6PD enzymatic activity according to spectrophotometry ranged from 0.05 to 22.57, with 
adjusted male median of 8.35 U/g Hb (100% activity). 
With minimal training, 
CareStart™ RDT is highly 
specific, feasible and a 
practical option for the 
identification of G6PDd male 
patients and its use may 
enable safer prescribing of PQ 
to decrease the burden from 
P.v relapse. 
G6PD Test Results
G6PD RDT RESULTS No. of G6PD normal 
cases read as deficient
No. of G6PDd cases read 
as normal G6PD
Trainees 37/960 5/960
Expert in field 23/960 6/960
Expert in lab 10/960 9/960
Results
• Assess CareStart™ performance in 
the hands of healthcare and village 
malaria workers vs. expert readers 
both in field and laboratory settings 
against reference lab quantitative 
test (Pointe Scientific, Inc. MI). 
• Develop training materials 
on G6PD and PQ to 
improve knowledge and 
acceptability of PQ use. 
The G6PD test results were not statistically significant 
between the groups. 
The mean knowledge score pre-training was 33.86%( VMWs) and 56.4% (nurses), with a rise to 89% and 90% 
post training (p <0.001). The improvement in knowledge scores was independent on years of experience, 
profession and education level (p=0.57, p=0.38).
Community engagement can have profound effect on PQ risk 
perceptions and integrating short training within community 
settings should be a priority with the planned deployment of 
PQ.
Most trainees were very receptive to the information provided 
about PQ and RDT testing, and were able to retain knowledge 
acquired during training.
Though the numbers were small, some G6PDd volunteers will 
be misclassified as normal and therefore, patient follow up, 
monitoring and patient counseling will be paramount to 
successful deployment of PQ in Cambodia. 
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I don’t know Not Willing Willing
Willingness to give radical cure PQ  to a 
patient with P.v
Level of comfort in providing PQ based on 
G6PD RDT results
Disclaimer: Material has been reviewed by the Walter Reed Army Institute of Research.  There is no objection to its presentation and/or 
publication.  The opinions or assertions contained herein are the private views of the author, and are not to be construed as official, or as 
reflecting true views of the Department of the Army or the Department of Defense.  The investigators have adhered to the policies for protection 


















































1- < 3 years














Scores improved post training for all levels of experience (p<0.001)
Training tools and G6PD 
counseling script were very 
effective
Outcome of our study denoted 
a highly sensitive test (96.8%) 
with high NPV, valuable in 
reducing risk when PQ is 
prescribed. 
CareStart™ G6PD Rapid Diagnostic Test 
offered at the point-of-care will alleviate 
the lack of testing for G6PDd, thereby 
lowering the risk of hemolysis when PQ is 
prescribed. 
